Glenmark Pharmaceuticals — 360° view

Glenmark Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹4,247 crore and net profit of ₹264 crore for the September 2026 quarter.

Glenmark Pharmaceuticals (NSE: GLENMARK) closed at ₹2,648.00 on 20 Nov 2026, up 41.0% over the past year. Its market capitalisation is ₹74,733 crore and it trades at 36.9 times earnings.

Share price
₹2,648.00 (20 Nov 2026)
Market cap
₹74,733 Cr (20 Nov 2026)
P/E
36.89 (20 Nov 2026)
Revenue
₹4,247 Cr (September 2026 quarter)
Net profit
₹264 Cr (September 2026 quarter)
ROCE
39.8% (FY26)
ROE
23.6% (FY26)
Book value
₹397 (FY26)
Dividend yield
0.09% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,714.00 / ₹1,825.10 (20 Nov 2026)
1-year return
41.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: GLENMARK

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.